Rothschild & Co Asset Management US’s ANI Pharmaceuticals ANIP Stock Holding History

Rothschild & Co Asset Management US’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.4M	Buy	+34,924	New	+$1.31M	0.02%	234

Other funds holding ANIP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.66B AUM 27.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Rothschild & Co Asset Management US's ANIP Position: Q4 2022 in Review

Rothschild & Co Asset Management US opened a new position in ANI Pharmaceuticals (ANIP) in Q4 2022: 34,924 shares worth $1.4M. The stake represents 0.02% of the portfolio and ranks #234 among its holdings.

126 funds tracked by Wall St. Rank hold ANIP as of Q4 2022.

Rothschild & Co Asset Management US held 34,924 shares of ANI Pharmaceuticals worth $1.4M as of Q4 2022.
ANI Pharmaceuticals was a new Rothschild & Co Asset Management US position in Q4 2022.
ANI Pharmaceuticals made up 0.02% of Rothschild & Co Asset Management US's portfolio in Q4 2022, its #234 holding.
126 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2022.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2022, filed 14 Feb 2023.